A carregar...

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

PURPOSE: Use of enzalutamide has produced a revolutionary change in the treatment of advanced prostate cancer. However, clinical resistance to enzalutamide can develop swiftly in initial responders. This study aimed to test whether overexpression of IL-6 and constitutive activation of Stat3 in prost...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate
Main Authors: Liu, Chengfei, Zhu, Yezi, Lou, Wei, Cui, Yuan Yuan, Evans, Christopher P., Gao, Allen C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4437226/
https://ncbi.nlm.nih.gov/pubmed/24307657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22741
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!